S-Quatre's MCB Provision Platform Business
First written in FY2025-H1. 1 of 2 entries say "Advanced", first in FY2025. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「The Company is also developing a platform business that uses the integrated system established through this process, S-Quatre® (S-Quatre), extending from recruiting baby-tooth donors to tooth extraction at partner medical institutions and MCB manufacturing at GMP facilities, to provide MCBs not only for its own pipeline but also to other companies developing cell-related pharmaceuticals, including regenerative medicine products and exosomes.」
The Company is formalizing its policy of developing S-Quatre's system, extending from material procurement to GMP manufacturing, as an MCB supply platform for other companies as well as for its own pipeline. - FY2025-H1First statedAnnual report
「The Company is also developing a platform business that uses the integrated system established through this process, S-Quatre® (S-Quatre), extending from recruiting baby-tooth donors to tooth extraction at partner medical institutions and MCB manufacturing at GMP facilities, to provide MCBs not only for its own pipeline but also to other companies developing cell-related pharmaceuticals, including regenerative medicine products and exosomes.」
The Company began developing a platform business using S-Quatre's system linking material procurement, medical institutions and GMP manufacturing, providing MCBs to other companies as well as for its own pipeline.